30 closest matches · ranked by relevance
Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis
Primary: The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 — 30.6; 24.0; 26.5; 14.3 Percentage of Participants — p=0.055
Nonalcoholic Steatohepatitis
Primary: Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS) — 19.15; 1.25 milliseconds (ms) — p=0.1621
Non-Alcoholic Steatohepatitis (NASH)
Primary: SAF Activity Score (SAF-A) Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score (CRN-F) — 41; 34; 22; 42 Participants — p==0.061
NASH - Nonalcoholic Steatohepatitis
Primary: Effect of Efruxifermin (EFX) vs Placebo on Fibrosis Regression in Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)-Associated Stage 2 or 3…
Non-Alcoholic Steatohepatitis (NASH)
Primary: Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) — 21…
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis With Liver Fibrosis
Primary: Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by…
NASH - Nonalcoholic Steatohepatitis
Primary: Main: Absolute Change From Baseline in Hepatic Fat Fraction Assessed by MRI-PDFF at Week 12. — -12.32; -13.44; -14.14; -0.29 Absolute percentage of hepatic fat
Hepatitis
Primary: Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category) — 9; 11; 5; 1 participants — p=<0.001
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver
Primary: Evaluation of Pooled Different-day, Different-operator Reproducibility of Shear Wave Speed Measurements — 30.7 Reproducibility coefficient (in %)
Non-alcoholic Steatohepatitis (NASH)
Primary: Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3)…
Non-alcoholic Steatohepatitis · Fatty Liver · Fibrosis, Liver
Primary: Number of NTZ Treated Participants Presenting Any Treatment Emergent Adverse Event (TEAE) — 20; 7; 10; 3 Participants
Hepatitis
Primary: Number of Patients With Improvement in Liver Histology — 12 participants
Nonalcoholic Steatohepatitis (NASH) · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events — 50; 60; 50; 25 percentage of participants
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
Non Alcoholic Steatohepatitis (NASH)
Primary: Percentage of Patients With Resolution of NASH, Defined as Disappearance of Ballooning (Score = 0) With Lobular Inflammation Score 0 or 1, With no Worsening of Fibrosis…
Non-alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis · NASH - Nonalcoholic Steatohepatitis
Primary: Number of Participants With Hepatic Histological Improvement in NAS — 22; 25; 27; 34 Participants — p=0.747
NASH - Nonalcoholic Steatohepatitis
Primary: Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis — 5; 12; 11; 1 Participants…
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) — 84.6; 85.0; 92.5; 88.6 percentage of participants
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants
NASH
Primary: Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 6; 4; 7; 7 Participants
Non-Alcoholic Steatohepatitis (NASH)
Primary: Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory…
NASH - Nonalcoholic Steatohepatitis
Primary: Liver Fibrosis Response After Administration With Aldafermin in Participants With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis — 0.24; 0.25; 0.27; 0.23 score on a…
Nonalcoholic Steatohepatitis
Primary: Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular…
Nonalcoholic Steatohepatitis (NASH)
Primary: Absolute Change in Hepatic Fat Fraction Based on MRI-PDFF Measurements in LPCN 1144 Treated Subjects Compared to Placebo. — -7.68; -9.17; -1.54 Percentage of liver fat…
Non-alcoholic Fatty Liver Disease (NAFLD) · Non-alcoholic Steatohepatitis (NASH)
Primary: Safety (Including Hepatic Safety) and Tolerability of MEDI0382 Compared With Placebo: Number of Participants With TEAE and SAE — 20; 22; 9; 0 Participants
Non-alcoholic Steatohepatitis (NASH)
Primary: Number of Participants With Adverse Events — 42; 41; 40; 42 Participants
Non-alcoholic Steatohepatitis
Primary: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) — -32.9; -10.4 percent…
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) +…
Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Primary: Relative to Baseline Alanine Aminotransferase (ALT) — 0.959; 0.895 Ratio — p=0.893
Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH)
Primary: Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) — 50; 23 participants — p=0.0002